RYSVX
Price
$279.85
Change
+$2.31 (+0.83%)
Updated
Aug 13 closing price
Net Assets
65.65M
VSCAX
Price
$32.72
Change
-$0.18 (-0.55%)
Updated
Aug 13 closing price
Net Assets
11.79B
Interact to see
Advertisement

RYSVX vs VSCAX

RYSVX vs VSCAX Comparison Chart in %
View a ticker or compare two or three
VS
RYSVX vs. VSCAX commentary
Aug 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RYSVX is a Buy and VSCAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCAX has more cash in the bank: 11.8B vs. RYSVX (65.6M). VSCAX pays higher dividends than RYSVX: VSCAX (0.21) vs RYSVX (0.01). RYSVX was incepted earlier than VSCAX: RYSVX (22 years) vs VSCAX (27 years). RYSVX (1.60) is less costly to investors than VSCAX (1.10). RYSVX is a more actively managed with annual turnover of: 3783.00 vs. VSCAX (79.00). VSCAX initial investment is less costly to investors than RYSVX (5%) vs RYSVX (5%). VSCAX has a lower initial minimum investment than RYSVX: VSCAX (1000) vs RYSVX (2500). VSCAX (32.09) and RYSVX (30.85) have marching annual gain over last year. VSCAX return over 5 years is better than : 64.09 vs. RYSVX (59.15).
RYSVXVSCAXRYSVX / VSCAX
Total Expense Ratio1.551.10141%
Annual Report Gross Expense Ratio1.601.10145%
Fund Existence22 years27 years-
Gain YTD25.78329.98886%
Front Load5%6%86%
Min. Initial Investment25001000250%
Min. Initial Investment IRAN/AN/A-
Net Assets65.6M11.8B1%
Annual Yield % from dividends0.010.216%
Returns for 1 year30.8532.0996%
Returns for 3 years53.4669.6777%
Returns for 5 years59.1564.0992%
Returns for 10 years126.43100.31126%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYDVX2.710.03
+1.12%
Royce Smid-Cap Total Return Service
SUHCX23.53N/A
N/A
DWS Health and Wellness C
MGTIX44.36N/A
N/A
MFS Massachusetts Inv Gr Stk I
FSCRX27.67N/A
N/A
Fidelity Small Cap Discovery
BIVRX17.53N/A
N/A
Invenomic Investor